Strengths of the study
To date this is the largest case series of paediatric patients sustaining vcp secondary to vincristine chemotherapy for ALL occurring within one tertiary referral centre within the UK. From this we were able to identify patterns such as laterality, onset of symptoms from commencing chemotherapy and therefore considerations towards management of future planned vincristine doses. Time for recovery and treatment interventions were also identified.
All our patients had no underlying medical conditions prior to being diagnosed with ALL nor where they on any medications known to increase the toxicity. We could therefore deduce our finding from a comparative selection of paediatric patients and compare our case series to other cases reported in the literature and guide clinicians faced with this clinical situation.